CRISPR–Enabled Epigenome Editing

Researchers apply the genome-editing technology to alter histones at distant gene enhancers, controlling gene expression.

Written byKerry Grens
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, ZEPHYRISAn enzyme borrowed from the CRISPR/Cas genome-editing system can be used to modify epigenetic marks to flip on gene enhancers and promoters and thereby manipulate gene expression, according to a report published in Nature Biotechnology today (April 6). The tool works by facilitating the acetylation of histones at specific promoters or enhancers.

“There are already drugs that will affect enhancers across the whole genome, but that’s like scorching the earth,” Timothy Reddy, a bioinformatician at Duke University and coauthor of the study, said in a press release. “I wanted to develop tools to go in and modify very specific epigenetic marks in very specific places to find out what individual enhancers are doing.”

So Reddy and his colleagues used an existing approach: they neutered the Cas9 nuclease, so that instead of chopping up DNA it would simply serve as a guide to get the molecular machinery to the right spot in the genome. Then, their modified enzyme—which was paired up with the core domain of a histone acetyltransferase—could induce transcription by tweaking acetylation of histones at particular ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies